Log in with your email address username.


[Correspondence] Risk of stent thrombosis with bioresorbable vascular scaffolds

After doing a meta-analysis of randomised controlled trials (Feb 6, p 537),1 Salvatore Cassese and colleagues concluded that everolimus-eluting bioresorbable vascular scaffolds (BVS) have greater definite or probable stent thrombosis risk than everolimus-eluting metallic stents. However, in their study, postdilation after BVS implantation was done in only 1588 (64%) of 2466 cases.